Ipamorelin: The Complete Guide
A five-amino-acid ghrelin-receptor agonist studied for growth-hormone release and gastrointestinal effects. Hormonal selectivity in an experiment does not establish an absence of other effects.
What is Ipamorelin?
Here is the simplest way to understand Ipamorelin: it is the second voice in the growth hormone conversation. CJC-1295 is the first voice — it stands in for the hypothalamic GHRH message that travels down to the pituitary. Ipamorelin uses a completely different pathway. It activates the ghrelin receptor, which is the same receptor your stomach uses to send its own message to the pituitary. Two different voices, both telling the same pituitary cells to release growth hormone.
Ipamorelin is a synthetic pentapeptide — just five amino acids — developed by Novo Nordisk in Denmark in the 1990s. They derived it from an earlier compound called GHRP-1 by removing two amino acids from the middle of the molecule. The result was unexpected: research suggests Ipamorelin became the first growth hormone secretagogue with selectivity comparable to natural GHRH itself.
The original discovery study reported a selective hormone-release profile under its experimental conditions. That finding should not be generalised to every endpoint or setting: the 2009 rat postoperative-ileus study reported increased food intake with repeated dosing.
Research Applications
Research on Ipamorelin spans the ghrelin/GH-secretagogue receptor pharmacology, the well-studied CJC-1295 + Ipamorelin combination protocol, and applications outside the GH axis itself — including gut motility research where the same receptor system shows activity.
Research suggests Ipamorelin releases growth hormone without raising cortisol, ACTH, or prolactin — even at doses far above the threshold for GH activity. This selectivity profile distinguishes it from earlier ghrelin-receptor compounds and is why it dominates current research protocols in the family.
Research suggests Ipamorelin activates the GHSR-1a receptor — the same receptor that stomach-derived ghrelin uses naturally to trigger growth hormone release. The same built-in pathway your body uses, activated by a designed peptide rather than the natural hormone.
Growth hormone influences lean tissue and fat metabolism, but cortisol breaks down lean tissue and stores fat — which makes most GH peptides messy research tools because they raise both. Research suggests Ipamorelin's clean profile gives researchers a more straightforward signal for body composition studies.
The most-studied pairing in growth hormone research. CJC-1295 stimulates the GHRH pathway; Ipamorelin stimulates the ghrelin pathway. Two different receptors on the same pituitary cells — research suggests activating both simultaneously produces more growth hormone release than either alone.
The ghrelin receptor is not only in the pituitary — it is also expressed throughout the digestive tract. A 2012 study measured gastric emptying after surgery in rats and reported an effect under those experimental conditions. This does not establish clinical benefit. The verified 2012 study replaces our earlier unverified 2007 citation.
Repeated dosing increased food intake in the 2009 rat postoperative-ileus study. This is evidence against describing Ipamorelin as having no appetite-related effects in all settings; it does not establish the response in people.
How Ipamorelin Works
The big-picture answer first: Ipamorelin works by activating the ghrelin receptor on pituitary cells. Research suggests this triggers growth hormone release through a signalling pathway separate from the GHRH pathway that CJC-1295 and Tesamorelin use. The two pathways converge on the same cells but enter through different doors.
The ghrelin receptor in plain language: ghrelin is a hormone made in the stomach that travels through the bloodstream to the brain. It is most famous as a "hunger hormone" — levels rise when you have not eaten, fall after meals. But ghrelin also binds to receptors on pituitary cells, where research suggests it triggers growth hormone release. The receptor is technically called GHSR-1a (Growth Hormone Secretagogue Receptor 1a). Ipamorelin is studied as an agonist at this receptor. Effects on hormone release, gastrointestinal transit and food intake need to be assessed separately.
Why scope matters: a selective hormone-release result is not a guarantee that food intake or other physiological pathways are unaffected. The endpoint, model and experimental conditions matter.
The CJC-1295 synergy mechanism: growth hormone-releasing pituitary cells (somatotrophs) have multiple receptors that all influence GH release. The GHRH receptor is one. The ghrelin receptor (GHSR-1a) is another. Research suggests when both receptors are activated at the same time, the GH release response is greater than either alone — sometimes substantially greater. CJC-1295 presses one button; Ipamorelin presses the other; the cell responds more strongly than to either button alone. This is the pharmacological basis for why CJC + Ipamorelin became the most-studied combination protocol in growth hormone research.
Metabolic stability: research suggests Ipamorelin has roughly five times lower plasma clearance than GHRP-6 — meaning more of the administered peptide stays intact in the body for longer. About 60-80% of the dose is recovered as intact peptide in bile and urine. This moderate stability is part of what makes it practical as a research tool.
Storage Guidelines
Store at 2–8°C in a cool, dry place. Protect from light and moisture. Refrigerate once in solution form.
Frequently Asked Questions
Technical Specifications
Compiled by the Southern Pacific Labs research team. Last updated April 2026.
Published References
- Venkova K, Mann W, Nelson R, et al. “Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.” The Journal of pharmacology and experimental therapeutics, 2009. PubMedA 2009 postoperative-ileus rat study. Repeated dosing increased food intake in this model, so it does not support a blanket claim of no appetite effects. These findings do not establish benefit or safety in people.
- Raun K, Hansen BS, Johansen NL, et al. “Ipamorelin, the first selective growth hormone secretagogue.” European journal of endocrinology, 1998. PubMedThe original Ipamorelin discovery paper from the Novo Nordisk research team. Established the selectivity profile (GH release without cortisol, ACTH, or prolactin) that defines the compound. The starting point of the entire Ipamorelin research field.
- Greenwood-Van Meerveld B, Tyler K, Mohammadi E, et al. “Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus.” Journal of experimental pharmacology, 2012. PubMedA 2012 rat study of postoperative gastric emptying. This verified study replaces the unverified 2007 citation; it is not the same publication.
- Svensson J, Lall S, Dickson SL, et al. “The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats.” The Journal of endocrinology, 2000. PubMedExamined the downstream effects of GH release stimulated by Ipamorelin (vs GHRP-6) on bone mineral content in research animals. Useful for understanding how the released GH translates into measurable tissue-level outcomes.
- Ishida J, et al. “Growth hormone secretagogues: history, mechanism of action, and clinical development.” JCSM Rapid Communications, 2020. SourceA comprehensive review of the entire GH secretagogue class — useful as a starting point for understanding where Ipamorelin sits relative to GHRP-2, GHRP-6, hexarelin, MK-677, and the other compounds in the broader research family.
Browse all Ipamorelin research on PubMed →
Related Research Guides
More in Growth Hormone & Endocrine
The most common Ipamorelin pairing — works on the GHRH pathway while Ipamorelin works on the ghrelin pathway. Two different receptors on the same pituitary cells, the most-studied combination protocol in growth hormone research.
Read guide →GHRH Analogue (FDA Approved)The FDA-approved GHRH analogue in the same cluster — Phase 3 trial data and full 44-amino-acid GHRH structure. Different mechanism than Ipamorelin (GHRH receptor instead of ghrelin receptor) but on the same pituitary cells.
Read guide →HGH FragmentA GH fragment that isolates the fat-metabolism activity of growth hormone without engaging the broader GH-release pathway. Different mechanism than Ipamorelin entirely — works downstream of GH rather than at the release step.
Read guide →